TorVaxFlu (Institute Torlak)

**TorVaxFlu** is a seasonal trivalent, split-virion, inactivated influenza vaccine developed and manufactured by the Institute of Virology, Vaccines and Sera Torlak in Serbia. It contains antigens from two influenza A subtypes, A/H1N1 and A/H3N2, and one influenza B virus component. The vaccine provides active immunization by inducing influenza-specific antibody responses and immunological memory; it cannot cause influenza because the viral material is inactivated. TorVaxFlu is supplied as a 0.5 mL suspension for injection in a pre-filled syringe and is intended for prevention of influenza in adults aged 18 to 65 years. Serbia granted market authorization for Torlak's trivalent seasonal influenza vaccine in August 2020. ([torlak.rs](https://torlak.rs/wp-content/uploads/2024/02/TorVaxFlu.pdf))

Brand names

TorVaxFlu

Other names

Torlak seasonal trivalent split inactivated influenza vaccineSerbian seasonal influenza vaccine